Prostate cancer is the most common cancer among British men, with one in 8 being affected over the course of their lifetime
Prostate cancer is the most common cancer among British men, with one in 8 being affected over the course of their lifetime

Radioactive prostate cancer drug given approval for NHS use

The powerful drug can specifically target tumourswhen given as an infusion to the blood stream

Siobhan Fenton
Health Correspondent
Friday 02 September 2016 12:27

A radioactive drug, similar to that which killed Russian former spy Alexander Litvinenko has been approved as a treatment for prostate cancer on the NHS.

Radium-223 is a powerful drug based on a mildly radioactive form of the metal radium. Given as an infusion into the bloodstream, it is taken up by bones and can specifically target tumours through alpha particles.

Infusions are typically given once a month, for up to six months.

The drugs emit the same type of radiation as polonium-210 which was used to assassinate former Russia spy Mr Litvinenko due to its ability to destroy tissues and organs. However, despite this, when used in a controlled manner, the same capabilities can be used to specifically target cancers.

The health regulation authority NICE has announced prostate cancer patients will now be able to access the drug on a routine basis. It has previously only been recommended for patients who had received initial treatment alongside an additional medicine, docetaxel.

Professor Carole Longson, director of the centre for health technology evaluation at NICE, said: “I am pleased we have been able to broaden our recommendations for radium-223. Patients with prostate cancer will surely benefit from this drug being available for routine NHS use. I hope we’ll see more drugs like this move into routine NHS use after companies have been able to better demonstrate cost-effectiveness.”

Prostate cancer is the most common cancer for men in the UK. Around 1 in 8 men will be affected by the condition during their lifeline.

An estimated 47,000 men are diagnosed with the cancer every year.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies


Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in